Setback lays bare Novo’s need in haemophilia
Novo Nordisk is in danger of being left behind in haemophilia, and new safety fears around its lead R&D project make this more likely. But could a setback prompt deal…
Lynparza's surprise stumble could finally bury cediranib
Another trial seems to suggest that adding VEGF blockade to Parp inhibition does little for patients without tumour mutations.
Seattle could waltz in where Astra failed
Despite Astrazeneca stacking the odds in its favour Imfinzi’s Danube trial, in first-line bladder cancer, reads out negatively.
Safety scare knocks Novartis
Heightened Beovu safety concerns could turn into a big problem for Novartis, while rival Regeneron will make the most of any uncertainty.
Another Alzheimer’s failure for Biogen bulls to shrug off
A fresh blow to the beta-amyloid hypothesis has not rattled Biogen's supporters, but Lilly shareholders were apparently hoping for more.
Ipsen’s quick fix backfires
A failed phase III trial has Ipsen clutching at straws to salvage its rare bone disease project palovarotene, which it bought for $1bn a mere 11 months ago.
Astra and Acasti throw the Amarin bulls more fodder
Amarin must hope that setbacks for Astrazeneca and Acasti show that in Vascepa it has the secret sauce.
Surprise! There’s a tumour in which Keytruda doesn’t work
The Merck & Co drug’s failure in small-cell lung cancer prompts a theory and leaves the way clear for Roche and Astrazeneca.
Clinical developments over the Christmas period
The most important clinical readouts of the holiday period concerned Google Health, Axsome, Wave and Spectrum.
